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To analyze the neutralizing-related activity of antibodies against the hypervariable region 1 (HVR1) of hepatitis C virus
(HCV) in more detail, monoclonal antibodies (mAbs) against HVR1 were raised by immunizing various strains of mice with one
of two synthetic HVR1 peptides that had been derived from two isolates of HCV. The epitope specificity of all six mAbs could
be assigned by the use of a series of linear peptides in competitive ELISA. It seems that most subregions in the amino acid
sequence of HVR1 can induce a humoral immune response in mice. All three mAbs specific to HVR1-6-1 had the ability to
capture homologous HCV-6 and inhibit its absorption to susceptible cells in vitro despite the fact that the epitope of each
mAb was at a different location in HVR1, whereas the other three mAbs specific to HVR1-7 could not capture HCV-6 nor inhibit
the absorption of HCV-6 to susceptible cells. The data in this study suggest that mAbs against HVR1 can prevent the
infectivity of HCV in an isolate-specific and epitope position-independent manner. © 2000 Academic PressINTRODUCTION
Hepatitis C virus (HCV) is an enveloped virus with a
positive-stranded RNA genome of nearly 9.5 kb encoding
a polyprotein of about 3000 amino acids, which is post-
translationally processed into functional proteins by cel-
lular and viral proteinases. The structural proteins are
located at the amino terminus, and include the core and
two envelope glycoproteins, E1 and E2. The nonstruc-
tural proteins including NS2–NS5 antigens are encoded
at the downstream end of the genome.
At the N-terminus of the E2 protein, there is a specific
region of approximately 27–31 amino acids (aa) in length
whose sequence shows considerable variability among
different HCV isolates. This region is termed hypervari-
able region 1 (HVR1) (Hijikata et al., 1991; Weiner et al.,
1991), and it has been postulated that the variability in
the amino acid sequence of HVR1 among different iso-
lates resulted from humoral immune pressure leading to
the selection of escape mutants (Weiner et al., 1992; Kato
et al., 1993). This interpretation has been further sup-
ported by the absence of such diversity in an agamma-
globulinemic patient with HCV infection (Kumar et al.,
1994), and by the relatively less variability in the HVR1
sequence among HCV-infected hypogammaglobuline-
mic patients (Booth et al., 1998) and among immunosup-
pressive patients (Ni et al., 1999) than among normal
HCV-infected patients. Indeed, antibodies to HVR1 in the1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 181-3-3972-8830. E-mail: mesumi@med.nihon-u.ac.jp.
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276human sera have the ability to block the absorption of
HCV to cells in vitro (Shimizu et al., 1994; Zibert et al.,
1995), and to protect chimpanzees from HCV infection
(Farci et al., 1994). Antibodies that were raised specifi-
cally against HVR1 in a rabbit inhibited viral infection in
a cell culture (Shimizu et al., 1996) and freed chimpan-
zees which were challenged by HCV from infection (Farci
et al., 1996). We also found that a chimpanzee in which
higher titers of anti-HVR1 antibodies had been induced
by active immunization with synthetic HVR1 peptides,
could protect itself from infection upon being challenged
by homologous HCV (Esumi et al., 1999). Therefore,
HVR1 may contain the neutralizing epitopes. However, it
is questionable whether HVR1 may be applied as a
candidate target for a vaccine because of the tremen-
dous heterogeneity in this region among different HCV
isolates. Although HVR1 shows great sequence variabil-
ity, we found that animal polyclonal anti-HVR1 antibodies
that had been raised against HCV-6, captured a different
isolate of HCV-7, and that the anti-HVR1-6 antibodies
cross-reacted with HVR1-7 (Esumi et al., 1998). We fur-
ther demonstrated that the cross-reactivity among HVR1
sequences was inducible by a single peptide immuniza-
tion in mice and in chimpanzees, and that cross-reactiv-
ity is not a rare event (Zhou et al., 1999). It appears that
broadly cross-reactive anti-HVR1 antibodies can be in-
duced with HVR1 peptides. Thus far, however, it remains
unclear whether anti-HVR1 antibodies have neutralizing
activity toward different HCV isolates. Therefore, it is of
great interest to develop monoclonal antibodies (mAbs)
specific to HVR1 to more specifically analyze the neu-
tralizing phenomenon of anti-HVR1 antibodies.
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277NEUTRALIZING ACTIVITY OF mAbs AGAINST HVR1 OF HCVTo date, cell culture systems in which efficient propa-
gation of HCV occurs in vitro, and readily available ani-
mal models of HCV replication in vivo, have not been
developed. In this study, we used alternative assays, i.e.,
the virus capture assay, which is based on the antibody–
virus interaction (Hijikata et al., 1993; Esumi et al., 1998),
and the assay of the inhibition of HCV absorption to
susceptible cells (Shimizu et al., 1996) to analyze the
biological characteristics of six mouse mAbs specific to
two HVR1 sequences, HVR1-6-1 and HVR1-7, which were
mutually cross-reactive for the polyclonal antibodies
(Esumi et al., 1998; Zhou et al., 1999). We attempted to
earch whether the mAbs have the neutralizing-related
apacity to the infectivity of both homologous and heter-
logous HCV isolates in vitro.
RESULTS
ffinity and epitopes of anti-HVR1 mAbs
Three hybridomas that secrete HVR1-6-1-specific
Abs, 30F1, 30F3, and 30F4, and three hybridomas that
ecrete HVR1-7-specific mAbs, 5A2, 5A3, and 5A9, were
roduced. The 24-amino acid peptide and the 31-amino
cid peptide of each of HVR1-6-1 and HVR1-7 that were
T
Synthetic HVR1 Peptides Used fo
Designation aa Positiona
6(1–31) 384–414 (1–31)
7(1–31) 384–414 (1–31)
6(1–24) 384–403 (1–24)
7(1–24) 384–403 (1–24)
6(1–10) 384–393 (1–10)
6(7–16) 390–399 (7–16)
6(11–20) 394–403 (11–20)
6(17–26) 400–409 (17–26)
6(22–31) 405–414 (22–31)
6(12–31) 395–414 (12–31)
6(12–30) 395–413 (12–30)
6(17–31) 400–413 (17–31)
7(1–10) 384–393 (1–10)
7(7–16) 390–399 (7–16)
7(11–20) 394–403 (11–20)
7(17–26) 400–409 (17–26)
7(22–31) 405–414 (22–31)
7(1–14) 384–397 (1–14)
7(1–12) 384–395 (1–12)
7(3–20) 386–403 (3–20)
7(5–20) 388–403 (5–20)
Note. Peptides 1–31 and 1–24 were used in the animal immunization
added at the C-terminus of these peptides to couple with the carrier pr
antigens in competitive ELISA. Amino acid residues are represented b
a Amino acid residues 384–414 at the N-terminus of the E2 protein
arentheses.sed for immunizing mice of various strains, are shown
n Table 1 (the first four peptides). Because we found that
o
mt was difficult to successfully produce anti-HVR1 mAbs
ith a strain of mice, we tried to immunize four strains of
ice to develop the mAbs specific to HVR1-6-1 and
VR1-7. Table 2 summarizes the general characteristics
f these mAbs. The affinity constant of each mAb to the
espective 31-aa peptide was determined by surface
lasmon resonance technology. As shown in Table 2, all
ix mAbs had a markedly low dissociation rate, and
herefore each had a high affinity constant, ranging be-
ween 0.78 and 2.54 3 10210 M. The titration curves of
hese mAbs against the respective HVR1 peptide in
LISA also indicated that these mAbs had comparable
ffinities (data not shown).
To define the linear epitopes responsible for mAb
ecognition, we performed competitive ELISA. The 24- or
1-aa peptide of HVR1-6-1 or HVR1-7 that had been
njected in the mice, was immobilized on ELISA plates,
nd a series of synthetic HVR1 peptides covering differ-
nt portions of the respective HVR1 sequence was used
s the soluble competing antigens. The aa sequences of
he HVR1 peptides coated on the plates and soluble
ompeting antigens are shown in Table 1. Figure 1
hows the representative results. The epitopes of mAbs
0F1 and 30F3 were located in aa 1–10 and in aa 11–20
nization and Competitive ELISA
aa Sequence
HTRVTGGVQGHVTSTLTSLFRPGASQKIQLV
A-YT---A-S-TLRGV--F-S---------I
HTRVTGGVQGHVTSTLTSLFRPGA
A-YT---A-S-TLRGV--F-S---
HTRVTGGVQG
GVQGHVTSTL
HVTSTLTSLF
TSLFRPGASQ
PGASQKIQLV
VTSTLTSLFRPGASQKIQLV
VTSTLTSLFRPGASQKIQL
TSLFRPGASQKIQLV
ATYTTGGAQS
GAQSHTLRGV
HTLRGVTSFF
TSFFSPGASQ
PGASQKIQLI
ATYTTGGAQSHTLR
ATYTTGGAQSHT
YTTGGAQSHTLRGVTSFF
TGGAQSHTLRGVTSFF
in ELISA as the antigens coated on the plate. A cysteine residue was
he other peptides of various lengths were used as competing soluble
ingle-letter code. Dashes indicate identical residues.
ignated as aa residues 1–31 of hypervariable region 1 (HVR1) in theABLE 1
r Immu
s, and
otein. T
y the sf HVR1-6-1, respectively (Fig. 1A), and the epitopes of
Abs 5A3 and 5A9 were defined in aa 7–16 and in aa
cid num
w
w
e
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278 ZHOU, SHIMIZU, AND ESUMI1–10 of HVR1-7, respectively (Fig. 1B); each synthetic
peptide with the sequence noted earlier exclusively and
nearly completely inhibited the reactivity of the respec-
tive mAb to the corresponding coated immunogen. The
T
Characteristics of M
mAb Mouse Immunogenb
ka (s
21M21)
(3105)
30F1 C57BL/6 6-1, 24 aa 3.71
30F3 BDF1 6-1, 31 aa 0.812
30F4 BALB/c 6-1, 31 aa 2.44
5A2 B6C3F1 7, 24 aa 2.57
5A3 B6C3F1 7, 24 aa 1.56
5A9 BDF1 7, 31 aa 1.70
a The binding activity of the mAb to the respective antigen was exam
constant; KD, affinity constant.
b Each mouse was immunized with either the full-length (31 aa) or the
or HVR1-7.
c The epitopes were determined by competitive ELISA. The amino a
FIG. 1. Epitope mapping of mAbs by competitive ELISA. Binding rea
as inhibited by various competing liquid-phase peptides. Before additi
ith different competing peptides. The aa sequences of the competin
xpressed as a percentage of the antibody binding activity of the respecti
reincubated with PBS instead of competing peptides. (A) mAbs against HVRepitope of mAb 30F4 was considered to be located in aa
12–30 of HVR1-6-1, since five 10-mer overlapping pep-
tides did not inhibit the reactivity between the mAb and
the immunogen, and only the peptides composed of aa
Abs against HVR1
g parametersa
Isotype
aa Position
of epitopec
kd (s
21)
(31025)
KD (M)
(310210)
7.71 2.08 IgG2b k 1–10
1.62 2.00 IgG2b k 11–20
1.90 0.78 IgG1b k 12–30
6.52 2.54 IgG2b k 3–14
2.65 1.70 IgG2a k 7–16
2.41 1.42 IgG2b k 1–10
BIACORE analysis. ka, association rate constant; kd, dissociation rate
peptide in which 7 aa at the C-terminus had been deleted, of HVR1-6-1
bers of mAb recognition refer to Table 1.
f each indicated mAb to the solid-phase corresponding immunogens
e ELISA plates, the mAbs at a certain concentration were preincubated
ides are shown in Table 1. The residual binding reactivity of mAbs isABLE 2
ouse m
Bindin
ined by
24-aactivity o
on to th
g peptve mAb subject to the same experiment, except that the mAb was
1-6-1; (B) mAbs against HVR1-7.
279NEUTRALIZING ACTIVITY OF mAbs AGAINST HVR1 OF HCV12–31 or aa 12–30 inhibited the reactivity (Fig. 1A). It is
likely that the amino acids at both ends of the peptide,
i.e., aa 12 to aa 16 and aa 21 to aa 30, played a critical
role in the recognition of this mAb because neither pep-
tide 17–31 nor peptide 11–20 inhibited the binding of the
mAb to the immunogen (Fig. 1A). The epitope of mAb 5A2
was defined to be aa 3–14 in HVR1-7 because peptides
1–14 and 3–20 inhibited the binding of the mAb to the
immunogen, whereas peptides 1–12 and 5–20 did not
show significant inhibition (Fig. 1B). The epitope location
of each of the six mAbs is summarized in Table 2. It
seems that most subregions in HVR1 can induce a hu-
moral immune response because the six epitopes of the
six mAbs together covered the entire HVR1 sequence.
In our previous study, we found that the polyclonal
antibodies against HVR1-6-1 and HVR1-7 induced in
mice and in chimpanzees were mutually cross-reactive,
and that both antibodies also cross-reacted with several
other HVR1 peptides (Esumi et al., 1998; Zhou et al.,
1999). Then, we attempted to examine whether the mAbs
against these two HVR1 sequences were also recipro-
cally cross-reactive. All three mAbs against HVR1-6-1
were not reactive toward either 24-aa or 31-aa HVR1-7
peptide, and the three mAbs against HVR1-7 were not
reactive toward either 24-aa or 31-aa HVR1-6-1 by ELISA
(data not shown). However, one of the three mAbs
against HVR1-6-1, 30F3, was cross-reactive to a different
HVR1 sequence (HVR1-S1-1), and one mAb against
HVR1-7, 5A9 was cross-reactive to another HVR1 se-
quence (HVR1-P33-1) (Zhou et al., 1999). The remaining
four mAbs were not reactive to each of the other seven
HVR1 peptides that were cross-reactively positive for the
mouse polyclonal antibodies (data not shown).
Virus capture by mAbs
Since an efficient in vitro replication system to propa-
gate HCV to examine the neutralizing ability of the hu-
moral immune response has not been developed, an
alternative assay to evaluate the biological functions of
the antibody was used to investigate the binding activity
of the antibody to the virus (Hijikata et al., 1993; Esumi et
al., 1998). We examined the binding activity of anti-HVR1-
6-1 mAbs to homologous HCV-6 by adding a second
antibody to immunoprecipitate the immune complexes.
The cross-binding ability of anti-HVR1-7 mAbs to heter-
ologous HCV-6 was also investigated because the poly-
clonal antibodies against HVR1-6-1 and those against
HVR1-7 induced in animals were mutually cross-reactive
(Esumi et al., 1998; Zhou et al., 1999). Figure 2 shows that
two mAbs specific to HVR1-6-1, 30F1 and 30F3, com-
pletely captured the homologous viral isolate, since HCV
RNA was detectable only in the precipitate and no HCV
RNA remained in the supernatant (Fig. 2A). Another mAb
specific to HVR1-6-1, 30F4, partially captured the virus
qualitatively as some of the HCV RNA was detectable inthe supernatant (Fig. 2A). On the other hand, the three
mAbs specific to HVR1-7 did not capture any of the
HCV-6, as HCV RNA was detected only in the superna-
tant and not in the precipitate after HCV-6 was mixed
with each of these three mAbs (Fig. 2B). The negative
control mAb did not capture HCV-6, as only the super-
natant was positive for HCV RNA as shown in Fig. 2C. We
did not examine the binding activity of the anti-HVR1-7
mAbs to homologous HCV-7 nor the cross-binding of
anti-HVR1-6-1 mAbs to HCV-7 since the viral isolate
HCV-7 was no longer available.
We previously found that mAb 30F3, which is specific
to HVR1-6-1, is cross-reactive to a different HVR1 se-
quence, HVR1-S1-1, and that mAb 5A9, which is specific
to HVR1-7, is cross-reactive to a different HVR1 se-
quence, HVR1-P33-1 (Zhou et al., 1999). We attempted to
assess whether these two cross-reactive mAbs could
capture the corresponding viral isolates. Unfortunately,
both HCV-S1 and HCV-P33 existed in the immune-com-
plex form in the serum after being subjected to the
immune-complex assay (Hijikata et al., 1993) and could
not be used in these experiments (data not shown).
Inhibition of HCV absorption to cells by mAbs
Although an in vitro culture system for HCV is not
available, an inhibition assay of viral absorption or at-
tachment to presumed susceptible cells has been devel-
oped for assessing the neutralizing-related capacity of
the antibodies (Shimizu et al., 1994, 1996; Zibert et al.,
FIG. 2. PCR-based virus capture assays with mAbs. The mAbs were
incubated with HCV-6, followed by the addition of anti-mouse IgG. The
bound and unbound viral particles were separated by centrifugation
into the supernatant (S) and precipitate (P), respectively. S and P were
each tested for the presence of HCV RNA by RT-PCR. (A) mAbs specific
to HVR1-6-1; (B) mAbs specific to HVR1-7; and (C) an unrelated mAb as
a negative control. Two independent experiments were performed with
the same results.1995). In this study we used the HPBMa 10.2 cell line to
examine the biological function of the mAbs. HPBMa
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280 ZHOU, SHIMIZU, AND ESUMI10.2 cells are susceptible to in vitro infection of several
HCV isolates, including HCV-6, and the infectivity of HCV
in this system is correlated with the infectivity of HCV in
vivo in chimpanzees (Shimizu et al., 1993). Actually, the
serum of a hyperimmune rabbit against HVR1, which
neutralized in vivo the infection of HCV (Farci et al., 1996),
inhibited HCV absorption and infection in vitro to HPBMa
10.2 cells (Shimizu et al., 1996).
A defined amount of HCV-6 was preincubated with
different concentrations of each mAb. Each mixture was
added to HPBMa 10.2 cells, and further incubated to
allow the unneutralized HCV to adsorb to the cells. Fig-
ure 3 shows the adsorbed HCV to the cells which was
detected by reverse transcription (RT) and nested-poly-
merase chain reaction (PCR). All three mAbs specific to
HVR1-6-1 dose-dependently inhibited the absorption of
HCV-6 to HPBMa 10.2 cells; HCV absorption to the cells
was not detected in HCV that had been preincubated
with higher concentrations of mAb (Fig. 3A). Even at an
mAb concentration of 0.3 mg/ml, mAbs 30F3 showed the
capacity to inhibit the binding of HCV-6 to HPBMa 10.2
cells (Fig. 3A). On the other hand, all three mAbs specific
to HVR1-7 (Fig. 3B) and the negative control mAb (Fig.
3C) could not prevent the attachment of HCV-6 to HPBMa
10.2 cells even at a higher concentration of 30 mg/ml.
hus, mAbs against HVR1 had the isolate-specific ab-
orption-inhibiting ability in an epitope position-indepen-
ent manner.
DISCUSSION
FIG. 3. Inhibition of HCV adsorption to HPBMa 10.2 cells by mAbs. A
specific amount of HCV-6 was preincubated in 0.3, 3, or 30 mg/ml of the
indicated mAb, and then the mixture was inoculated to HPBMa 10.2
cells. The quantity of cell-attached HCV was estimated by detecting
HCV RNA with RT-PCR. (A) HCV-6 was preincubated in 0.3, 3, or 30
mg/ml of an mAb specific to HVR1-6-1. (B) HCV-6 was preincubated in
3 or 30 mg/ml of an mAb specific to HVR1-7. (C) HCV-6 was preincu-
ated in 3 or 30 mg/ml of an unrelated mAb as a negative control. Each
experiment was repeated twice and the same results were obtained.HVR1 in HCV has been thought to contain neutralizing
pitopes. In this study, we generated and characterized
tix mouse mAbs against two different HVR1 sequences
nd used them to investigate the neutralizing-related
roperties in vitro. We report for the first time that mAbs
gainst HVR1 can capture HCV and inhibit the absorp-
ion of HCV to susceptible cells in an isolate-specific
anner. These neutralizing-related activities were not
ependent on the position of the epitope within HVR1;
hat is, antibody directed against many epitopes in HVR1
i.e., antibody against the N-terminus, middle region, or
-terminus of HVR1) had the capacity to prevent HCV
nfection. This is in contrast with the observation by
ibert et al. (1997) that only anti-HVR1 antibodies di-
ected against the epitope at the N-terminus were effec-
ive in eliminating HCV infection in HCV-infected pa-
ients, and in preventing HCV binding to human fibroblast
ells in vitro. However, anti-HVR1 antibodies directed to
he C-terminal region of HVR1 raised in a rabbit blocked
CV absorption to the cells (Shimizu et al., 1996), and
oreover proved to have neutralizing activity in chimpan-
ees challenged by the mixture of antibodies and homol-
gous HCV (Farci et al., 1996). In our HVR1 vaccine
xperiment, we also found that a high titer of anti-HVR1
ntibodies that were directed mainly to the C-terminal
egion of HVR1, could protect a chimpanzee from the
CV challenge (unpublished data). Taken together,
herefore, we consider that not only anti-HVR1 antibodies
irected to the N-terminal region, but also antibodies to
he other subregions of HVR1 have neutralizing activity to
revent the infectivity of HCV. This suggests that the
ntire HVR1 sequence of 31 aa at the N-terminus of the
2 protein is probably exposed outside and sterically
ree on the envelope of HCV, and that any of these
ifferentially recognizing antibodies against HVR1 easily
ind to the virion surface to inhibit the virus–host inter-
ction. However, the true neutralizing activity of the
Abs remains to be further confirmed by experimental
nfection in chimpanzees because the methods we used
ere surrogate of the neutralizing assessment.
In addition, the epitopes of the three mAbs raised
gainst HVR1-7 were also found to be in various loca-
ions within the HVR1 sequence (Fig. 1B). These data
ndicate that most subregions in the HVR1 sequence can
nduce a humoral immune response. This can be ex-
lained by the observation that HVR1 lacks a strongly
redictive tertiary structure (Weiner et al., 1992). Linear
pitopes tend to be associated with less-structured re-
ions of proteins, especially the ends of proteins. mAb
0F4, however, seemed to be induced not against a
imple linear epitope, but against a semiconformational
pitope because both short subregions within aa 12–16
nd aa 21–30 were requisite for mAb recognition (Fig.
A). This suggests that the combined structure of these
wo subregions was an epitope, or that the remaining
ubregion structure constructed by the interaction of thewo subregions was the epitope.
HVR1 could be of interest for vaccine development. A
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281NEUTRALIZING ACTIVITY OF mAbs AGAINST HVR1 OF HCVbroadly reactive humoral immune response to HVR1 was
inducible in mice and chimpanzees (Puntoriero et al.,
1998; Zhou et al., 1999). However, it remains unclear
whether a broadly neutralizing antibody response is in-
ducible. We tried to examine such broadly neutralizing
activity at the mAb level. Unfortunately, we did not pro-
duce anti-HVR1-7 mAbs cross-reactive to HVR1-6-1;
therefore, such cross-neutralizing activity still remains to
be clarified. We actually produced cross-reactive mAbs
against different HVR1 (Zhou et al., 1999); however, the
orresponding HCV isolates were not available for the
eutralizing assessment in this study. We previously
ound one broadly cross-reactive epitope located in the
-terminal subregion of HVR1, aa 24–31 (Zhou et al.,
999). Unfortunately, in this study we did not produce
Abs that recognized aa 24–31 epitope. This may ex-
lain that the mAbs against HVR1-6-1 and HVR1-7 were
ot cross-reactive. The mAb against this subregion
hould be produced to assess the cross-neutralizing
bility, to solve the challenging issue of how to overcome
he high variability of the amino acids in HVR1 and
nduce a broadly neutralizing antibody response, for the
evelopment of an HCV vaccine using HVR1.
MATERIALS AND METHODS
ouse mAbs and peptides
Monoclonal antibodies specific to HVR1-6-1, desig-
ated as 30F3, and mAbs specific to HVR1-7, designated
s 5A9, were generated by immunizing BDF1 mice as
reviously described (Zhou et al., 1999). Another mAb to
HVR1-6-1, designated 30F4, was produced by immuniz-
ing BALB/c mice intralymphonodularly at both inguinal
regions three times at an interval of 1–2 weeks with
peptide 6(1–31) (Table 1). A monoclonal antibody specific
to HVR1-6-1, designated as 30F1, in the C57BL/6 strain,
and two monoclonal antibodies specific to HVR1-7 in the
B6C3F1 strain, designated as 5A2 and 5A3, were gener-
ated by intraperitoneally immunizing mice four times at
an interval of 1–2 weeks with HVR1 peptides of 24 aa in
length in which the 7 aa at the C-terminus had been
deleted, i.e., 6(1–24) or 7(1–24) (Table 1). Lymphonodular
cells or spleen cells from the immunized mice were
fused with myeloma cells P3-X63-Ag8-U1 (P3U1) from
the BALB/c strain, and hybridomas were selected and
maintained as previously described (Zhou et al., 1999). A
protein A column was used for affinity purification of
mAbs from ascites fluid. The mAb isotype was deter-
mined with a Mouse-Hybridoma Subtyping Kit (Boeh-
ringer-Mannheim, Germany).
HVR1 peptides were synthesized using F-moc technol-
ogy on a Shimadzu PSSM-8 Automated Synthesizer
(Kyoto, Japan), purified by high-performance liquid chro-
matography (HPLC) using a SynProPep column (type
RPC18, 20 3 150 mm, Shimadzu), and then coupled with
an equal amount of maleimide-activated keyhole limpet
t
themocyanin (KLH; Pierce, Rockford, IL) through a car-
boxyl-terminal cysteine residue as described previously
(Esumi et al., 1998). The aa sequences of the HVR1
peptides used in this study are shown in Table 1. In
addition to the peptides used in the immunization, other
overlapping peptides for each of HVR1-6-1 and HVR1-7
that span the full-length of HVR1 (Table 2) were synthe-
sized for linear epitope mapping as previously described
(Zhou et al., 1999).
Affinity assessed by BIACORE
The antigen-binding property of each mAb was exam-
ined by biointeraction analysis using the BIACORE 2000
Biosensor (Biacore AB, Uppsala, Sweden). The purified
synthetic HVR1 peptides, 6(1–31) and 7(1–31), to which a
cysteine residue was added at the C-terminus, were
immobilized on CM5 sensor chips by the use of the thiol
coupling method according to the manufacturer’s in-
structions. Various concentrations of each purified mAb
were applied at a flow rate of 50 ml/min for 3 min in HBS
unning buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3
M EDTA, 0.005% Surfactant P20), and the dissociation
as measured with HBS running buffer for 30 min. The
urface of the sensor chip was regenerated by 1-min
ulses of 10 mM glycine–HCl buffer (pH 1.75). The rate
onstants of the association (ka) and dissociation phases
kd) were calculated using the BIAevaluation software.
An apparent affinity constant (KD) was calculated as the
ratio of kd to ka.
ELISA and epitope mapping
The ELISA for screening antibodies to HVR1 and test-
ing the cross-reactivity of the mAbs was performed with
synthetic peptides essentially as described previously
(Ahmed et al., 1996). The epitope on the HVR1 sequence
that was recognized by each mAb was determined by
competitive ELISA as previously described (Zhou et al.,
1999). Briefly, the wells of microtiter plates (Nunc,
Roskilde, Denmark) were coated with 100 ml of a 31- or
24-aa HVR1 peptide (Table 1) in 0.05 M carbonate buffer
at a concentration of 1 mg/ml, washed with phosphate-
buffered saline (PBS) containing 0.05% Tween 20 (PBS-T),
and blocked with 5% skim milk in PBS-T. Following a
second wash, 100 ml of appropriately diluted mAbs that
ad been preincubated with different concentrations of
ompeting peptides (Table 1) for 1 h at 37°C, was added
nd this was incubated for 1 h. Following the addition of
eroxidase-conjugated goat anti-mouse polyvalent im-
unoglobulins (Sigma, St. Louis, MO) and color devel-
pment, the absorbency at 450 nm was measured with a
ultiskan Bichromatic System (Labsystems Inc., Hel-
inki, Finland). The remaining binding reactivity of the
Ab was expressed as the percentage of the binding ofhe mAb measured under identical conditions, except
hat the competing peptides were replaced by PBS.
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The virus capture assay of mAbs was performed es-
sentially as described previously (Esumi et al., 1998).
Serum 6 (HCV-6) was obtained from a blood donor who
was positive for both anti-HCV and HCV RNA, and was
provided by a research group supported by Grants-in-Aid
from the Japanese Ministry of Health and Welfare. The
serum diluted by 1022 times in PBS, was centrifuged at
6,000 rpm for 15 min at 4°C, and 50 ml of the superna-
ant was mixed with 5 ml of each mAb (1 mg/ml in PBS).
he mixtures were incubated for 1 h at 4°C, and then 50
ml of 2 mg/ml of anti-mouse IgG goat F(ab9)2 (Organon
Teknika, Durham, NC) was added. After further incuba-
tion for 1 h at 4°C, each mixture was centrifuged at 2800
rpm for 15 min at 4°C and separated into the supernatant
and the pellet. Both the supernatant and the pellet were
subjected to detection of HCV RNA by RT-nested PCR as
described later. HCV was considered to be entirely cap-
tured by the mAb if HCV RNA was found only in the pellet
and not in the supernatant. HCV was considered to be
partially captured if both the supernatant and pellet con-
tained HCV RNA. If HCV RNA was detected only in the
supernatant, it meant that HCV was not captured.
Inhibition of HCV absorption to cultured cells
The HPBMa 10.2 cell line (Yoshikura, 1989) was used
in the absorption of HCV isolates as previously de-
scribed (Shimizu et al., 1993, 1996). The cells were cul-
tured in RPMI 1640 medium with 8% heat-inactivated
fetal calf serum. One hundred microliters of undiluted or
serial, 10-fold-diluted patient serum was added to 1 ml of
the cell suspension of HPBMa 10.2 cells (5 3 105 cells).
After incubation at 37°C for 2 h, the cells were washed
twice with PBS by centrifugation at 1000 rpm at 20°C for
5 min. The pellet was subjected to detection of cell-
adsorbed HCV RNA by RT-nested PCR as described
later. The absorption titer of HCV to HPBMa 10.2 cells
was estimated to be the sample of maximum dilution that
was positive for HCV RNA. The absorption titer of HCV-6,
whose genome titer in the serum was 105/ml, was 103/ml,
hich is approximately equal to the absorption titer of
03.5/ml reported by Shimizu et al. (1993).
Inhibition of HCV absorption to HPBMa 10.2 cells was
performed as previously described (Shimizu et al., 1996)
ith some modification. One hundred microliters of the
arget virus corresponding to 100 absorption titers per
illiliter, was incubated with an equal volume of different
mounts of mAbs in PBS at 4°C overnight. Each mixture
as inoculated to 1 ml of the cell suspension of HPBMa
0.2 cells (5 3 105 cells), and the following steps for
determining the absorption titer are the same as those
described earlier. The mAbs were inactivated at 56°C for
30 min before mixing with the target virus, and another
mAb unrelated to HCV was used as the negative control.RT-PCR
Total RNA was extracted with TRIzol Reagent (Life
Technologies, Gaithersburg, MD), and was reverse-tran-
scribed into cDNA with the RNA PCR Kit (Takara, Kyoto,
Japan) using 50 pmol 9-mer random primer and 5 U Avian
Myeloblastosis virus (AMV) reverse transcriptase in 20
ml of mixture. Half of the cDNA was subjected to nested
PCR with the use of 1 U AmpliTaq Gold polymerase (PE
Applied Biosystems, Foster City, CA) and 15 pmol of
primers in a volume of 50 ml. One-tenth of the first PCR
product was applied to a second round of PCR. The
primers were the same as those previously reported
(Esumi et al., 1998; Zhou et al., 1999). The thermal cycles
of PCR were one cycle of 9 min at 95°C, 35 cycles of 30 s
at 94°C, 60 s at 60°C, 60 s at 72°C, followed by extension
at 72°C for 7 min.
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